Hirofumi Kamada

Hirofumi Kamada

Auto-generated profile, based on publicly available information

Hirofumi Kamada

Department of Dermatology Iwate Medical University Iwate Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2025 in The Journal of Dermatology
Verified
Journal Article
Open access
WSWataru Sasaki
Wataru Sasaki
RSRyo Saito
Ryo Saito
KSKenta Suzuki
Kenta Suzuki
DWDaisuke Watanabe
Daisuke Watanabe
MMMasako Minami‐Hori
Masako Minami‐Hori
MSMariko Sugawara‐Mikami
Mariko Sugawara‐Mikami
Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study, we aimed to investigate the incidence, clinical characteristics, and timing of cutaneous manifestations associated with nemolizumab treatment in patients with AD, and to explore potential associations with baseline disease severity and immunological parameters. We conducted a multicenter retrospective study involving 219 patients aged ≥ 13 years with AD who received nemolizumab at 13 institutions in Japan between August 2022 and February 2024. Cutaneous eruptions were classified into six categories based on clinical consensus. Patients who received fewer than three doses without developing skin reactions were excluded. Clinical and laboratory parameters were compared between patients with and without cutaneous manifestations. Cutaneous manifestations occurred in 88 patients (40.2%), most commonly within the first three doses. Erythema was the most frequent presentation (69.3%), and 62.5% of eruptions were non‐pruritic. No significant associations were observed between the occurrence of skin reactions and baseline eczema area and severity index scores, eosinophil counts, serum immunoglobulin E, or thymus and activation‐regulated chemokine levels. Two cases of bullous pemphigoid were identified. Despite topical corticosteroid treatment, nemolizumab therapy was discontinued in 42% of the patients affected. In conclusion, nemolizumab frequently induces early‐onset, morphologically distinct cutaneous eruptions that appear to be independent of baseline disease severity or biomarkers.

19 February 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
HKHirofumi Kamada
Hirofumi Kamada
SYShinji Yasuhira
Shinji Yasuhira
MSMasahiko Shibazaki
Masahiko Shibazaki
HAHiroo Amano
Hiroo Amano
CMChihaya Maesawa
Chihaya Maesawa

19 December 2024 in The Journal of Dermatology
Verified
Journal Article
Closed access
HKHirofumi Kamada
Hirofumi Kamada
NANobuyuki Arakawa
Nobuyuki Arakawa
MKMarino Kato
Marino Kato
TTTakayuki Tanji
Takayuki Tanji
DWDaisuke Watabe
Daisuke Watabe
HAHiroo Amano
Hiroo Amano

1 April 2024 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
TITsuyoshi Inoue
Tsuyoshi Inoue
DWDaisuke Watabe
Daisuke Watabe
MFMaiko Furukawa
Maiko Furukawa
MGMaki Goto
Maki Goto
HKHirofumi Kamada
Hirofumi Kamada
HAHiroo Amano
Hiroo Amano